NCT02420847View on ClinicalTrials.gov

Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 3, 2015

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Urothelial CarcinomaTransitional Cell CarcinomaUnresectable Transitional Cell Carcinoma

Interventions

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Ixazomib Citrate

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02420847 - Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter